Infusion of Pituitary Adenylate Cyclase-Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: The pathogenesis of rosacea is incompletely understood. Signaling neuropeptides, including PACAP, a regulator of vasodilation and edema, are upregulated in rosacea skin. Here, we evaluated PACAP38-induced rosacea features and examined whether a 5-HT1B/1D receptor agonist could reduce these features.
METHODS: A total of 35 patients with erythematotelangiectatic rosacea received an intravenous infusion of 10 pmol/kg/minute of PACAP38 followed by an intravenous infusion of 4 mg sumatriptan or placebo (saline) on two study days in a double-blind, randomized, placebo-controlled, and cross-over trial.
RESULTS: PACAP38 increased facial skin blood flow by 90%, dilated the superficial temporal artery by 56%, and induced prolonged flushing and facial edema. Compared with placebo, sumatriptan reduced PACAP38-induced facial skin blood flow for 50 minutes (P = 0.023), constricted the superficial temporal artery for 80 minutes (P = 0.010), and reduced duration of flushing (P = 0.001) and facial edema (P < 0.001).
CONCLUSIONS: We established a clinical experimental model of rosacea features and showed that sumatriptan was able to attenuate PACAP38-induced rosacea flushing and edema. Findings support a key role of PACAP38 in rosacea flushing pathogenesis. It remains unknown whether PACAP38 inhibition can improve rosacea.
TRIAL REGISTER: The trial was registered at ClinicalTrials.govNCT03878784 in March 2019.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
The Journal of investigative dermatology - 141(2021), 7 vom: 21. Juli, Seite 1687-1698 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wienholtz, Nita Katarina Frifelt [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8R78F6L9VO |
|---|
| Anmerkungen: |
Date Completed 23.11.2021 Date Revised 23.11.2021 published: Print-Electronic ClinicalTrials.gov: NCT03878784 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jid.2021.02.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321596269 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321596269 | ||
| 003 | DE-627 | ||
| 005 | 20231225180150.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jid.2021.02.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1071.xml |
| 035 | |a (DE-627)NLM321596269 | ||
| 035 | |a (NLM)33600826 | ||
| 035 | |a (PII)S0022-202X(21)00119-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wienholtz, Nita Katarina Frifelt |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Infusion of Pituitary Adenylate Cyclase-Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.11.2021 | ||
| 500 | |a Date Revised 23.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03878784 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The pathogenesis of rosacea is incompletely understood. Signaling neuropeptides, including PACAP, a regulator of vasodilation and edema, are upregulated in rosacea skin. Here, we evaluated PACAP38-induced rosacea features and examined whether a 5-HT1B/1D receptor agonist could reduce these features | ||
| 520 | |a METHODS: A total of 35 patients with erythematotelangiectatic rosacea received an intravenous infusion of 10 pmol/kg/minute of PACAP38 followed by an intravenous infusion of 4 mg sumatriptan or placebo (saline) on two study days in a double-blind, randomized, placebo-controlled, and cross-over trial | ||
| 520 | |a RESULTS: PACAP38 increased facial skin blood flow by 90%, dilated the superficial temporal artery by 56%, and induced prolonged flushing and facial edema. Compared with placebo, sumatriptan reduced PACAP38-induced facial skin blood flow for 50 minutes (P = 0.023), constricted the superficial temporal artery for 80 minutes (P = 0.010), and reduced duration of flushing (P = 0.001) and facial edema (P < 0.001) | ||
| 520 | |a CONCLUSIONS: We established a clinical experimental model of rosacea features and showed that sumatriptan was able to attenuate PACAP38-induced rosacea flushing and edema. Findings support a key role of PACAP38 in rosacea flushing pathogenesis. It remains unknown whether PACAP38 inhibition can improve rosacea | ||
| 520 | |a TRIAL REGISTER: The trial was registered at ClinicalTrials.govNCT03878784 in March 2019 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Pituitary Adenylate Cyclase-Activating Polypeptide |2 NLM | |
| 650 | 7 | |a Sumatriptan |2 NLM | |
| 650 | 7 | |a 8R78F6L9VO |2 NLM | |
| 700 | 1 | |a Christensen, Casper Emil |e verfasserin |4 aut | |
| 700 | 1 | |a Coskun, Hande |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ditte Georgina |e verfasserin |4 aut | |
| 700 | 1 | |a Ghanizada, Hashmat |e verfasserin |4 aut | |
| 700 | 1 | |a Egeberg, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Thyssen, Jacob P |e verfasserin |4 aut | |
| 700 | 1 | |a Ashina, Messoud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of investigative dermatology |d 1945 |g 141(2021), 7 vom: 21. Juli, Seite 1687-1698 |w (DE-627)NLM000018597 |x 1523-1747 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2021 |g number:7 |g day:21 |g month:07 |g pages:1687-1698 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jid.2021.02.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2021 |e 7 |b 21 |c 07 |h 1687-1698 | ||